Karyopharm Therapeutics Inc. (KPTI) News
Follow Karyopharm Therapeutics Inc. (KPTI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 23 public stories across 9 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Karyopharm to Be Delisted From Nasdaq After Chapter 11 Filing
Nasdaq notified Karyopharm Therapeutics on November 4 that it would delist the company's securities. Karyopharm will not appeal; trading is scheduled to be suspended November 11, with shares expected to move to OTC tradi
EQUITY | Nov 07, 2026, 02:06 PM UTC
M
Karyopharm Secures Unanimous Lender Support for Prepackaged Chapter 11 Restructuring
EQUITY | Nov 03, 2026, 11:12 AM UTC
M
Karyopharm to Serve as Stalking Horse Bidder in Merger
A SEC filing says Karyopharm Therapeutics will serve as stalking horse bidder for a merger with a reorganized company.
MNA | Nov 03, 2026, 11:10 AM UTC
H
Karyopharm Therapeutics Files for Bankruptcy, Plans Merger
Karyopharm Therapeutics filed for bankruptcy and plans to merge with Ayrmid Ltd. The company said it entered a restructuring support agreement with existing lenders and noteholders and plans to continue ordinary operatio
EQUITY | Nov 02, 2026, 06:07 PM UTC
M
Karyopharm shares plunge after bankruptcy filing and merger plan with Ayrmid
Karyopharm shares fell sharply after a bankruptcy filing and a merger plan with Ayrmid.
MNA | Nov 02, 2026, 02:08 PM UTC
M
Karyopharm Therapeutics Files for Chapter 11 and Agrees to Merger
Karyopharm filed voluntary Chapter 11 petitions and entered a support agreement to merge with Ayrmid through a court-supervised sale. The company secured commitments for up to $55 million in debtor-in-possession financin
MNA | Nov 02, 2026, 02:07 PM UTC
M
Karyopharm Announces Planned Merger With Ayrmid
Karyopharm Therapeutics announced a planned merger with Ayrmid Ltd. The company says it remains focused on supporting patients and advancing its multiple myeloma programs.
MNA | Nov 02, 2026, 12:16 PM UTC
M
Karyopharm Secures Up to $55 Million in DIP Financing
Karyopharm Therapeutics secured up to $55 million in debtor-in-possession financing from existing lenders.
EQUITY | Nov 02, 2026, 12:15 PM UTC
M
Karyopharm Therapeutics Q3 Results Preview: EPS Estimate at $(0.95)
Karyopharm Therapeutics is scheduled to report Q3'26 results on October 29. EPS is estimated at $(0.95); the release time is unspecified.
EQUITY | Oct 28, 2026, 11:05 AM UTC
L
KPTI reports Nasdaq Rule 5635(c)(4) inducement grants
Karyopharm Therapeutics says it reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:06 PM UTC
L
Karyopharm grants 1,850 RSUs to two newly hired employees
Karyopharm Therapeutics Inc. announced it granted an aggregate of 1,850 restricted stock units (RSUs) to two newly-hired employees under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 01, 2026, 08:06 PM UTC
L
Karyopharm reports Q2 revenue of $33.4 million, reaffirms 2026 guidance
Karyopharm Therapeutics reported second-quarter revenue of $33.4 million, down from $37.9 million a year earlier, and reaffirmed 2026 revenue guidance of $130 million to $150 million.
EARNINGS | Aug 13, 2026, 12:54 PM UTC
L
Karyopharm Therapeutics affirms FY2026 sales guidance at $130M-$150M
Karyopharm Therapeutics (NASDAQ: KPTI) affirms FY2026 sales guidance of $130.000 million-$150.000 million versus a $133.736 million estimate, keeping the same range.
EARNINGS | Aug 13, 2026, 11:32 AM UTC
L
Karyopharm (KPTI) reports Q2 2026 financial results; myelofibrosis sNDA progress
Karyopharm (KPTI) reports second-quarter 2026 financial results and highlights continued progress toward a myelofibrosis sNDA submission, according to the company’s release.
EARNINGS | Aug 13, 2026, 11:30 AM UTC
H
Crude Oil Gains 1%; Apple Shares Tumble After Q3 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 200 points on Friday. The Dow traded up 0.38% to 52,406.69 while the NASDAQ rose 0.25% to 25,184.43. The S&P 500 also rose, gainin
EARNINGS | Jul 31, 2026, 04:02 PM UTC
H
KPTI Plunges 71% Premarket
KPTI drops 71% premarket
EQUITY | Jul 31, 2026, 12:47 PM UTC
H
KPTI Downgraded to Neutral
KPTI downgraded to Neutral from Buy
EQUITY | Jul 31, 2026, 11:55 AM UTC
H
Why Amazon Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
Shares of Amazon.com Inc (NASDAQ: AMZN ) rose sharply in pre-market trading after the company posted upbeat financial results for the second quarter. Amazon reported second-quarter revenue of $200.61 billion, beating the
EARNINGS | Jul 31, 2026, 08:50 AM UTC
H
KPTI Plunges 57% After Trial Update
KPTI falls 57% on trial news
EQUITY | Jul 30, 2026, 08:41 PM UTC
H
Karyopharm Therapeutics to request priority review
Karyopharm seeks priority review for selinexor
EQUITY | Jul 30, 2026, 08:29 PM UTC
L
KPTI Karyopharm Therapeutics - to submit snda to FDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis
KPTI Karyopharm Therapeutics - to submit snda to FDA in August 2026 for selinexor plus ruxolitinib in myelofibrosis
REGULATION | Jul 30, 2026, 08:07 PM UTC
L
KPTI KPTI - Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
KPTI KPTI - Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
EQUITY | Jul 30, 2026, 08:06 PM UTC
L
KPTI -23% on day; Karyopharm Therapeutics Slides on Disclosure of Cash-Retention Program for Executives (out Friday) Link To Story from MARK
KPTI -23% on day; Karyopharm Therapeutics Slides on Disclosure of Cash-Retention Program for Executives (out Friday) Link To Story from MARKETWATCH.com
EQUITY | Jul 20, 2026, 07:30 PM UTC